Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

XORTX Therapeutics Clarifies Halt of Trading in Canada and Timing for Commencement of Trading ...

November 4, 2021 GMT

CALGARY, Alberta, Nov. 04, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (TSXV: XRTX | NASDAQ: XRTX), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, wishes to clarify that the Company’s common shares were halted on both the TSX Venture Exchange (the “TSXV”) and the Canadian Securities Exchange (the “CSE”) to finalize the de-listing procedures required on the CSE.  The common shares will be de-listed from the CSE at close of market today and the common shares will re-commence trading tomorrow, Friday, November 5, on the TSXV under the trading symbol XRTX. 

Shareholders are not required to exchange their share certificates or take any other action in connection with the TSXV listing, as there will be no change in the CUSIP for the common shares.

About XORTX Therapeutics Inc.


XORTX Therapeutics Inc. is a pharmaceutical company with two clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for acute kidney injury associated with Coronavirus / COVID-19 infection and XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future health of patients. Additional information on XORTX Therapeutics is available at

For further information, please contact:

Allen Davidoff, CEONick Rigopulos, Director of Communications or +1 403 455  or +1 617 901 0785
Dr. David Sans, Head of Corporate Development in New York City or +1 347 573 0541

The TSX Venture Exchange and Nasdaq have neither approved nor disapproved the contents of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.